A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease

Inclusion Criteria

• •Main Inclusion: Part 1
• •Independent Ethics Committee (IEC)-approved written Informed Consent and privacy language as per national regulations must be obtained from the subject or legally authorized representative prior to any study-related procedures (including withdrawal of prohibited medication, if applicable).
• •Male subject and his female spouse/partner who is of childbearing potential must be using highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and continue throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
• •Male subject must not donate sperm starting at screening and throughout the study period and for at least 90 days after final study drug administration.
• •Female subject must be either:
• •* post-menopausal (defined as at least one year without any menses) prior to screening, or
• •* premenarchal prior to screening, or
• •* documented surgically sterile or status post hysterectomy (at least 1 month before screening), or
• •* if of childbearing potential, must have a negative urine pregnancy test at screening and must be using highly effective contraception. All females of childbearing potential will be required to use highly effective contraception consisting of 2 forms of birth control (1 of which must be a barrier method) starting at screening and throughout the study period and for 28 days (or 5 half-lives of the study drug whichever is longer) after final study drug administration.
• •Female subject must not be lactating, and must not be breast feeding at screening or during the study period and for 28 days \[or 5 half-lives of the study drug whichever is longer\] after final study drug administration.
• +84 more criteria